Clinical trial
Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant…
NCT00098098 · DynPort Vaccine Company LLC, A GDIT Company, Industry · Completed
Key facts
| NCT number | NCT00098098 |
|---|---|
| Title | Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults |
| Official title | A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults |
| Lead sponsor | DynPort Vaccine Company LLC, A GDIT Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | RECOMBINANT BOTULINUM VACCINE A/B |
| Intervention type | Biological |
| Interventions | rBV A/B |
| Enrollment | 44 |
| Start date | Aug 1, 2004 |
| Completion | Aug 1, 2005 |
| First posted | Dec 6, 2004 |
| Last update posted | Aug 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: